BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,777.70
- Market cap
- ₹4,26,530 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 35.3×Sector 45.9×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Other annual report announcements
All →Datakosa Annual Report
Bodhtree Consulting filed its 44th Annual Report for FY 2025-26 with the AGM notice for September 9, 2026. It reports no new transaction or financial event.
Morarka Finance Annual Report
Morarka Finance filed its 2025-26 Annual Report and AGM notice for the July 15, 2026 meeting. Agenda includes Pranay Morarka's Managing Director appointment and remuneration.
Venlon Enterprises Annual Report
Venlon Enterprises filed its 2025-26 Annual Report ahead of its September 18, 2026 AGM. The notice seeks approval for three related-party transactions.
Gujarat Peanut and Agri Products Annual Report
Gujarat Peanut And Agri Products filed a resubmitted Annual Report for FY 2025-26 after an earlier filing went under the wrong module. The report shows turnover of Rs. 38,932.71 Lakhs and PAT of Rs. 738.30 Lakhs.
Patel Chem Specialities Annual Report
Patel Chem Specialities filed its Annual Report for FY2025-26, covering corporate overview, product suite and company profile pages. The filing is a full annual report with no discrete transaction or event.
Bhavik Enterprises Annual Report
Bhavik Enterprises rectifies an error in Notes 3.3 and 3.4 of its FY2025-26 audited financial statements. Promoter holdings were overstated by 10,00,000 shares that were sold in the IPO offer for sale.